知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

8989 records (took 0.031 seconds)

    Pharmaceutical preparation comprising recombinant HCG
    2.
    发明授权
    Pharmaceutical preparation comprising recombinant HCG 有权

    公开(公告)号：US12234272B2

    公开(公告)日：2025-02-25

    申请号：US17709296

    申请日：2022-03-30

    Applicant: Ferring B.V.

    Inventor： Ian Cottingham ,  Daniel Plaksin ,  Richard White

    IPC: C07K14/575 ,  A61K38/16 ,  C07K14/59 ,  C12P21/00

    Abstract: Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and optionally follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises α2,3- and α2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using α2,3-sialyltransferase.

    Variable diameter bioreactors
    5.
    发明授权
    Variable diameter bioreactors 有权

    公开(公告)号：US12227723B2

    公开(公告)日：2025-02-18

    申请号：US18162774

    申请日：2023-02-01

    Applicant: Lonza Ltd

    Inventor： Michael Mietzner ,  Rajesh Beri ,  Edward Gunderson

    IPC: C12M1/00 ,  C12M1/06 ,  C12M1/36 ,  C12P21/00

    Abstract: A variable diameter bioreactor vessel is provided that includes a first vessel section having a first diameter configured to hold a liquid media and biologic material, and a second vessel section having a second diameter that is greater than the first diameter such that the liquid media can be increased from a first volume to a second volume within the vessel.

    RECOMBINANT COLLAGEN, EXPRESSION METHOD AND USE THEREOF
    7.
    发明申请
    RECOMBINANT COLLAGEN, EXPRESSION METHOD AND USE THEREOF 有权

    公开(公告)号：US20250051422A1

    公开(公告)日：2025-02-13

    申请号：US18507236

    申请日：2023-11-13

    Applicant: Shandong D-nutrimec Biomedical Co., Ltd.

    Inventor： Zhidong GUO ,  Jiajia SHAO ,  Hongwei MA ,  Huawei AI

    IPC: C07K14/78 ,  A61K9/00 ,  C12N9/24 ,  C12N15/85 ,  C12P21/00

    Abstract: Provided are a recombinant collagen, an expression method and use thereof. In the present disclosure, the recombinant collagen is expressed by a human embryonic kidney cell Expi293F at a high protein expression level, thereby realizing the expression of a large-molecular-weight recombinant collagen. Activity studies have showed that the expressed recombinant collagen has desirable activity in promoting cell migration, while the recombinant collagen III+I with a fusion tag shows high stability at 4° C. In addition, cell activity studies have shown that the recombinant type III collagen expressed by human cells has better activity in promoting the cell migration than that of a commercially available type III collagen. These results indicate that the human cell expression system is conducive to the expression of highly active and large-molecular-weight recombinant collagen.

    FUCOSIDASE MUTANTS AND THE USE THEREOF
    8.
    发明申请
    FUCOSIDASE MUTANTS AND THE USE THEREOF 有权

    公开(公告)号：US20250043325A1

    公开(公告)日：2025-02-06

    申请号：US18777939

    申请日：2024-07-19

    Applicant: CHO PHARMA, INC.

    Inventor： WEI-SHEN WU ,  KUO-CHING CHU

    IPC: C12P21/00 ,  C12N9/24

    Abstract: The present disclosure relates to a novel mutant form of α-fucosidase (α-L-fucosidase), which exhibits enhanced α-(1,6) fucosidase activity. The present disclosure also relates to the compositions comprising the novel mutant form of α-fucosidase, and the methods of using the novel mutant form of α-fucosidase to cleave α-(1,6)-linked fucoses in the glycoconjugates.

    RNAYLATION
    9.
    发明申请
    RNAYLATION 有权

    公开(公告)号：US20250002962A1

    公开(公告)日：2025-01-02

    申请号：US18293313

    申请日：2022-04-21

    Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. ,  Universität Heidelberg

    Inventor： Katharina HÖFER ,  Andres JÄSCHKE

    IPC: C12P21/00 ,  C07K14/245 ,  C12N9/10

    Abstract: The present invention relates to a method for attaching a 5′-nicotinamidnucleobasedinucleotide (NND)-capped nucleic acid sequence to a fusion protein or to a complex, comprising (a) contacting (i) a heterologous fusion protein which comprises a poly(peptide) of interest being fused to a tag, or (ii) a complex wherein a protein is under physiological conditions complexed with a tag with the 5′-NAD-capped nucleic acid sequence and an ADP-ribosyltransferase (ART) under conditions wherein the 5′-NND-capped nucleic acid sequence is covalently attached to the tag, wherein the tag comprises a recognition motif of the ART and preferably comprises or consists of (i) SEQ ID NO: 1 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif DVRPVRD (SEQ ID NO: 7) is conserved and preferably SEQ ID NO: 7 is conserved; (ii) SEQ ID NO: 2 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif DVRPVRD (SEQ ID NO: 7) is conserved and preferably SEQ ID NO: 7 is conserved; (iii) SEQ ID NO: 3 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif DVRPVRD (SEQ ID NO: 7) is conserved and preferably SEQ ID NO: 7 is conserved; (iv) SEQ ID NO: 4 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif LADGVEGYLRASEASRDRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved; (v) SEQ ID NO: 5 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif LADGVEGYLRASEASRDRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved; or (vi) SEQ ID NO: 6 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif LADGVEGYLRASEASRDRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved.

Patent Agency Ranking